glp 1 agonists microdose GLP-1 Microdosing vs. Standard Dosing: A Provider-Guided Comparison Microdosing GLP-1s: Does It Work?

The trial met its primary endpoint, demonstrating that semaglutide 7.2 mg led to significantly greater weight loss at week 72 compared to placebo

You may be eligible to file a GLP-1 blindness lawsuit if you: Used a GLP-1 medication (such as Ozempic, Wegovy, or Mounjaro) Experienced significant vision loss or were diagnosed with NAION or another serious optic condition Can provide medical records linking your vision impairment to your use of the drug An experienced GLP-1 vision loss lawyer can evaluate your case and determine whether you meet the criteria for legal action

From 2019 to 2024, among all adult patients with an overweight or obesity diagnosis, the percentage who were prescribed a GLP-1 drug but did not have bariatric surgery increased from 2.5 percent in 2019 to 11.2 percent in 2024, a relative increase of 339.5 percent

However, these hypotheses need further investigation

Telemetric intracranial pressure catheters enabled long-term intracranial pressure monitoring

Tirzepatide expanded the field by targeting both GIP and GLP-1 pathways